InnoCare Pharma is a commercial-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases, listed in Hong Kong and Shanghai.
InnoCare Pharma receives Chinese drug regulator approval for the IND of ICP-B381, its first bispecific antibody-drug conjugate. The candidate targets PSMA and STEAP1 and is approved to begin clinical trials in solid tumors, including prostate cancer.
InnoCare Pharma reports first-half 2026 revenue of RMB 1.1 billion, up 55.5%, and profit of RMB 239.7 million. The company also reports that TYK2 inhibitors soficitinib and fadeucravacitinib each achieved primary-endpoint wins in Phase III trials. The results mark sustained profitability.
InnoCare Pharma says China has approved a registrational Phase III head-to-head trial of its BCL2 inhibitor mesutoclax plus azacitidine against venetoclax plus azacitidine in treatment-naive AML. The trial compares both combinations in previously untreated patients, with overall survival as the endpoint.
InnoCare Pharma says its orelabrutinib and mesutoclax combination receives Breakthrough Therapy Designation in China for previously treated marginal zone lymphoma. The company cites ASCO 2026 data showing a 100% response rate.
